loadpatents
Patent applications and USPTO patent grants for FREEMAN; DANIEL J..The latest application filed is for "combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer".
Patent | Date |
---|---|
Combination Of Monalizumab, Durvalumab, Chemotherapy And Bevacizumab Or Cetuximab For The Treatment Of Colorectal Cancer App 20220211847 - ABDULLAH; SHAAD ESSA ;   et al. | 2022-07-07 |
K-ras mutations and anti-EGFr antibody therapy Grant 11,155,876 - Freeman , et al. October 26, 2 | 2021-10-26 |
Methods For Selection And Expansion Of T Cells Expressing Pd-1 App 20200199567 - HANABUCHI; SHINO ;   et al. | 2020-06-25 |
Nucleic Acid Biomarker And Use Thereof App 20200140954 - SCHNEIDER; Matthias ;   et al. | 2020-05-07 |
Protein Biomarker And Uses Thereof App 20200115467 - SCHNEIDER; Matthias ;   et al. | 2020-04-16 |
K-ras Mutations And Anti-egfr Antibody Therapy App 20190048423 - Freeman; Daniel J ;   et al. | 2019-02-14 |
Material and methods for treating or preventing HER-3 associated diseases Grant 9,988,462 - Hettmann , et al. June 5, 2 | 2018-06-05 |
Material And Methods For Treating Or Preventing Her-3 Associated Diseases App 20180134805 - HETTMANN; THORE ;   et al. | 2018-05-17 |
Material and methods for treating or preventing HER-3 associated diseases Grant 9,803,025 - Hettmann , et al. October 31, 2 | 2017-10-31 |
Protein Biomarker And Uses Thereof App 20170166654 - SCHNEIDER; Matthias ;   et al. | 2017-06-15 |
Nucleic Acid Biomarker And Use Thereof App 20170166973 - SCHNEIDER; Matthias ;   et al. | 2017-06-15 |
Material And Methods For Treating Or Preventing Her-3 Associated Diseases App 20160222126 - Hettmann; Thore ;   et al. | 2016-08-04 |
Material and methods for treating or preventing HER-3 associated diseases Grant 9,101,760 - Hettmann , et al. August 11, 2 | 2015-08-11 |
Methods of selecting epidermal growth factor receptor (EGFr) binding agents Grant 9,097,729 - Freeman , et al. August 4, 2 | 2015-08-04 |
Nucleic Acid Biomarker And Use Thereof App 20150152508 - SCHNEIDER; Matthias ;   et al. | 2015-06-04 |
Protein Biomarker And Uses Thereof App 20150147326 - SCHNEIDER; Matthias ;   et al. | 2015-05-28 |
Methods Of Selecting Epidermal Growth Factor Receptor (egfr) Binding Agents App 20150051091 - Freeman; Daniel J. ;   et al. | 2015-02-19 |
Antibodies directed to HER-3 and uses thereof Grant 8,771,695 - Rothe , et al. July 8, 2 | 2014-07-08 |
Material And Methods For Treating Or Preventing Her-3 Associated Diseases App 20140017166 - HETTMANN; THORE ;   et al. | 2014-01-16 |
Epidermal growth factor receptor mutations Grant 8,546,107 - Freeman , et al. October 1, 2 | 2013-10-01 |
Epidermalgrowth Factor Receptor Mutations App 20120328620 - FREEMAN; Daniel J. ;   et al. | 2012-12-27 |
Use Of Her3 Binding Agents In Prostate Treatment App 20120156130 - HETTMANN; Thore ;   et al. | 2012-06-21 |
Antibodies Directed to HER-3 and Uses Thereof App 20120058122 - Rothe; Mike ;   et al. | 2012-03-08 |
Material and methods for treating or preventing HER-3 associated diseases App 20110229406 - HETTMANN; THORE ;   et al. | 2011-09-22 |
Methods of selecting epidermal growth factor receptor (EGFR) binding agents Grant 7,985,559 - Freeman , et al. July 26, 2 | 2011-07-26 |
Epidermal growth factor receptor mutations Grant 7,981,605 - Freeman , et al. July 19, 2 | 2011-07-19 |
Antibodies Directed to HER-3 and Uses Thereof App 20100183631 - Rothe; Mike ;   et al. | 2010-07-22 |
Methods of selecting epidermal growth factor receptor (EGFR) binding agents App 20090123937 - Freeman; Daniel J. ;   et al. | 2009-05-14 |
Antibodies directed to HER-3 and uses thereof App 20080124345 - Rothe; Mike ;   et al. | 2008-05-29 |
Epidermal growth factor receptor mutations App 20070048754 - Freeman; Daniel J. ;   et al. | 2007-03-01 |
Formulations for non-viral in vivo transfection in the lungs Grant 6,022,737 - Niven , et al. February 8, 2 | 2000-02-08 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.